Article
Evaluation of Direct susceptibility testing method for Moxifloxacin against Mycobacterium tuberculosis using the BACTEC MGIT 960 system
2026-03-23
Abstract excerpt
<title>Abstract</title> <p>Background Moxifloxacin is a key component of current MDR-TB therapy regimens. The choice to include it in therapy at standard or higher doses is based on the lack or presence of resistance mutations conferring low-level or high-level resistance to moxifloxacin, as detected by the Line probe assay (LPA). Due to inherent phenotypic and genotypic discordance, such resistance must be reco...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e65cdd32-261e-5694-844d-2a3f33aa83bd
- DOI
- 10.21203/rs.3.rs-8884055/v1
